Get started
Author

Galia Oberkovitz

Proapoptotic BID Is an ATM Effector in the DNA-Damage Response
2005 · Iris Kamer, Rachel Sarig, et al. · Cell · 226
PDF
The ATM–BID pathway regulates quiescence and survival of haematopoietic stem cells
2012 · Maria Maryanovich, Galia Oberkovitz, et al. · Nature Cell Biology · 152
BL‐8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open‐label safety and efficacy phase 2a study
2020 · Gautam Borthakur, Yishai Ofran, et al. · Cancer · 43
PDF
PKCη confers protection against apoptosis by inhibiting the pro-apoptotic JNK activity in MCF-7 cells
2009 · Noa Rotem-Dai, Galia Oberkovitz, et al. · Experimental Cell Research · 34
PKCη expression contributes to the resistance of hodgkin's lymphoma cell lines to apoptosis
2007 · Sara Abu-Ghanem, Galia Oberkovitz, et al. · Cancer Biology & Therapy · 29
PDF
Nucleocytoplasmic shuttling of BID is involved in regulating its activities in the DNA-damage response
2007 · G Oberkovitz, L Regev, et al. · Cell Death and Differentiation · 16
CXCR4 antagonist (BL-8040) to enhance antitumor effects by increasing tumor infiltration of antigen-specific effector T-cells.
2018 · Pankaj Gaur, Vivek Verma, et al. · Journal of Clinical Oncology · 9
Evaluation of pharmacodynamic (PD) biomarkers in patients with metastatic pancreatic cancer treated with BL-8040, a novel CXCR4 antagonist.
2018 · Manuel M. Hidalgo, Ron Epelbaum, et al. · Journal of Clinical Oncology · 6
The Selective Anti Leukemic Effect of BL-8040, a Peptidic CXCR4 Antagonist, Is Mediated By Induction of Leukemic Blast Mobilization, Differentiation and Apoptosis: Results of Correlative Studies from a Ph2a Trial in Acute Myeloid Leukemia
2016 · Gautam Borthakur, Martin S. Tallman, et al. · Blood · 5
Effect of BL-8040, high-affinity CXCR4 antagonist, on T-cell infiltration, tumor growth, and synergy with immunomodulatory agents.
2017 · Michal Abraham, Inbal Mishalian, et al. · Journal of Clinical Oncology · 3
Open-label phase 1/2 study evaluating the tolerability and antitumor activity of selinexor and pembrolizumab in colorectal cancer.
2022 · Talia Golan, Talia Shentzer Kutiel, et al. · Journal of Clinical Oncology · 1
The CXCR4 Antagonist BL-8040 Induces a Robust Mobilization of CD34+CD38−CD45RA−CD90+ CD49f+ HSCs with Long-Term and Secondary Myeloid and Lymphoid Repopulating Activity
2017 · Michal Abraham, Galia Oberkovitz, et al. · Blood · 1
Final Phase IIa Study Results Evaluating the CXCR4 Antagonist BL-8040 in Combination with Cytarabine (Ara-C) for the Treatment of Relapsed/Refractory AML Patients
2016 · Gautam Borthakur, Martin Tallman, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Evaluation of pharmacodynamic (PD) biomarkers in patients with metastatic pancreatic cancer treated with BL-8040, a novel CXCR4 antagonist.
2018 · Manuel M. Hidalgo, Ron Epelbaum, et al. · Journal of Clinical Oncology
Combinatorial Targeting of Leukemia and Stromal Cells Overcomes Fms-like Tyrosine Kinase 3 (FLT3) Inhibitor Resistance in Acute Myeloid Leukemia (AML)
2017 · Seemana Bhattacharya, Hong Mu, et al. · Clinical Lymphoma Myeloma & Leukemia
Works count: 15
Citation count: 526
H-index: 7
I10-index: 6
Year
Topic
Type